Liu Xinghui, Yang Miao, Lip Gregory Y H, McDowell Garry
Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool L7 8TX, UK.
Department of Cardiovascular Medicine, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Biomedicines. 2024 May 12;12(5):1071. doi: 10.3390/biomedicines12051071.
Hypertension (HT) is a disease that poses a serious threat to human health, mediating organ damage such as the cardiovascular (CV) system, kidneys, central nervous system (CNS), and retinae, ultimately increasing the risk of death due to damage to the entire vascular system. Thus, the widespread prevalence of hypertension brings enormous health problems and socioeconomic burdens worldwide. The goal of hypertension management is to prevent the risk of hypertension-mediated organ damage and excess mortality of cardiovascular diseases. To achieve this goal, hypertension guidelines recommend accurate monitoring of blood pressure and assessment of associated target organ damage. Early identification of organ damage mediated by hypertension is therefore crucial. Plasma biomarkers as a non-invasive test can help identify patients with organ damage mediated by hypertension who will benefit from antihypertensive treatment optimization and improved prognosis. In this review, we provide an overview of some currently available, under-researched, potential plasma biomarkers of organ damage mediated by hypertension, looking for biomarkers that can be detected by simple testing to identify hypertensive patients with organ damage, which is of great significance in clinical work. Natriuretic peptides (NPs) can be utilized as a traditional biomarker to detect hypertension-mediated organ damage, especially for heart failure. Nevertheless, we additionally may need to combine two or more plasma biomarkers to monitor organ damage in the early stages of hypertension.
高血压(HT)是一种对人类健康构成严重威胁的疾病,它介导诸如心血管(CV)系统、肾脏、中枢神经系统(CNS)和视网膜等器官的损伤,最终因整个血管系统受损而增加死亡风险。因此,高血压的广泛流行给全球带来了巨大的健康问题和社会经济负担。高血压管理的目标是预防高血压介导的器官损伤风险和心血管疾病的额外死亡率。为实现这一目标,高血压指南建议准确监测血压并评估相关靶器官损伤。因此,早期识别高血压介导的器官损伤至关重要。血浆生物标志物作为一种非侵入性检测方法,有助于识别那些将从优化降压治疗和改善预后中获益的高血压介导器官损伤患者。在本综述中,我们概述了一些目前可用的、研究不足的、潜在的高血压介导器官损伤的血浆生物标志物,寻找能够通过简单检测来识别有器官损伤的高血压患者的生物标志物,这在临床工作中具有重要意义。利钠肽(NPs)可作为一种传统生物标志物来检测高血压介导的器官损伤,尤其是对于心力衰竭。然而,我们可能还需要结合两种或更多种血浆生物标志物来监测高血压早期阶段的器官损伤。